Keywords: Hospital-acquired infections, Generic erosion, Decision Resources, Vibativ, Teflaro, Torezolid, Theravance, Astellas, Forest, AstraZeneca, Trius, Forest
Generic erosion will constrain hospital-acquired infections drug market growth through 2019
Article | 14 December 2010
The advent of generic versions of nine branded agents will significantly constrain growth in the hospital-acquired infections (HAI) drug market ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Novo Nordisk's diabetes drug Victoza produced 8% weight loss in Ph III obesity trial
- Proposal to list Roche's Neulastim and Actemra in New Zealand
- Alchemia and Merck Serono collaborate on HA-Irinotecan with Erbitux
- Positive new data on Novartis' Galvus in elderly type 2 diabetes patients
- Johnson & Johnson expects 10 NDA filings by 2017, saying pharma sector poised for growth
